This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment





SAN FRANCISCO, March 19, 2013 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to enhanced detection and prevention of cardiovascular disease through innovative diagnostic tests, announced that Douglas Harrington, MD, Clinical Professor of Pathology at USC and Aviir Inc. CEO, addressed a select group of physicians and leading cardiologists on the Latest Advances in Cardiovascular Risk Assessment at a special invitation-only reception in San Francisco . The event took place March 10, during the American College of Cardiology (ACC) 2013 Annual Conference and included guest speakers Thomas Quertermous, PhD, Professor of Cardiovascular Medicine from the Stanford University School of Medicine, and Americo Simonini, MD, Cardiologist at Cedars-Sinai Medical Center.

(Logo: http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

"Our goal is to present and discuss the best cardiac risk assessment methods available. Presenting next generation tests like MIRISK VP with fellow physicians in an intimate forum enabled a free exchange and the chance to discuss advances in the field of preventative cardiology," said Dr. Harrington.

Many physicians at the event elected to take the MIRISK VP test on-site, which was offered by GUARDaHEART, a national non-profit dedicated to heart disease awareness and prevention.

MIRISK VP stratifies the intermediate risk group, which has proven to be a critical part of risk assessment, as most adverse cardiac events happen to intermediate risk individuals. In fact, MIRISK VP was shown in a peer-reviewed publication to significantly improve cardiac risk assessment by reclassifying intermediate risk individuals to either high or low risk groups, resulting in a net reclassification index of 43% compared to the standard Framingham method.

"As a cardiologist, I am excited about the prospect of this test. I understand its value to my patients and practice and I was happy to speak to my colleagues about its usefulness in the clinic," stated Dr. Simonini.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,466.65 -96.65 -0.58%
S&P 500 1,921.06 -9.61 -0.50%
NASDAQ 4,336.94 -32.8330 -0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs